Although in multiple myeloma cells, tumor regression has been observed in xenografts following treatment with MLN2238 (Chauhan et al., 2011), we found that treatment with MLN2238 of SMARCB1 deficient xenografts led to a cytostatic response. The gene discussed is SMARCB1; the disease is neoplasm.